Categories AllCompany newsData & digitalESGIndustry recognitionsIndustry trendsLeadership appointmentsPartnerships & collaborationsPatient-focusRegionalSocial mediaTherapeutic areas Year All20262025 May 26, 2026 Can a chaotic FDA still deliver on faster drug development? Read more May 20, 2026 Four factors that can define CGT clinical outcomes: sequence, dose, route and administration Read more May 19, 2026 Parexel-Vitrana Deal: The Promise of AI-Enabled, Single-Partner Pharmacovigilance Read more May 18, 2026 US pharma executives note increasing importance of Chinese R&D Read more May 18, 2026 Parexel Launches ParexelAI Suite of Human-Led AI Services for Clinical Trials Read more May 7, 2026 What was lost at the FDA Read more April 30, 2026 Parexel Acquires Vitrana to Expand AI-Enabled Patient Safety and Pharmacovigilance Technology Read more April 30, 2026 Parexel Acquires Vitrana for AI Pharmacovigilance Platform Read more April 30, 2026 Parexel acquires Vitrana to expand pharmacovigilance technology platform Read more April 29, 2026 FDA launches pilot for real-time clinical trials Read more April 27, 2026 S.Biomedics Selects Parexel as Contract Research Organization (CRO) to Accelerate U.S. Development of TED-A9 for Parkinson’s Disease and Japanese Market Entry Read more April 22, 2026 After Contributing 30% of Global Innovation Assets, What’s Next for China’s Innovative Drug Industry? Read more April 20, 2026 How Sponsors Should Be Structuring Development Plans Around the Plausible Mechanism Framework Right Now Read more April 17, 2026 The Evidentiary Risks of Natural History Data and How to Approach External Control Comparability Read more April 17, 2026 What Sites, Sponsors, Vendors, And CROs Can All Agree On Read more April 16, 2026 Where Master Protocols Are Most Vulnerable Under the Plausible Mechanism Framework Read more April 15, 2026 How Regulators Assess Substantial Evidence When Trial Populations Are Too Small for Traditional Designs Read more April 14, 2026 Opinion: Adopting a patient-centric approach is a competitive advantage Read more April 14, 2026 How FDA's Plausible Mechanism Framework Changes the Path to Approval for Individualized Therapies Read more March 17, 2026 5 Ways to Secure Biotech Funding in 2026 Read more March 11, 2026 Catalyst announces four new members of Board of Directors Read more March 10, 2026 Four strategies for executing complex, international phase 3 breast cancer trials Read more March 4, 2026 Parexel Execs On Trials In War Zones, Biotech 'Green Shoots', China Action and DCT Rework Read more March 2, 2026 Scientifically rigorous and resolutely empathetic: how pharmacovigilance programmes can elevate the patient voice Read more February 27, 2026 Equitable Care, Accelerated Timelines: Expanding Global Access to Rare Disease Research Read more February 26, 2026 Finding Hope for FRRS1L Selects Parexel for Regulatory and Investigational New Drug (IND) Support with US Food and Drug Administration (FDA) Read more February 19, 2026 2026 Space Awards: Triangle's top commercial real estate developments Read more February 14, 2026 India becoming backbone of global clinical research Read more February 3, 2026 Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions Read more February 2, 2026 Industry calls Union Budget 2026 a defining moment for India's biopharma future Read more January 31, 2026 India's Biosimilars Prowess: Transitioning to A Strategic Global Hub Read more January 21, 2026 India at a jumping-off point in terms of commitment to global clinical studies Read more January 16, 2026 Analytical Strategies for Aseptic Processing Read more
May 20, 2026 Four factors that can define CGT clinical outcomes: sequence, dose, route and administration Read more
May 19, 2026 Parexel-Vitrana Deal: The Promise of AI-Enabled, Single-Partner Pharmacovigilance Read more
April 30, 2026 Parexel Acquires Vitrana to Expand AI-Enabled Patient Safety and Pharmacovigilance Technology Read more
April 27, 2026 S.Biomedics Selects Parexel as Contract Research Organization (CRO) to Accelerate U.S. Development of TED-A9 for Parkinson’s Disease and Japanese Market Entry Read more
April 22, 2026 After Contributing 30% of Global Innovation Assets, What’s Next for China’s Innovative Drug Industry? Read more
April 20, 2026 How Sponsors Should Be Structuring Development Plans Around the Plausible Mechanism Framework Right Now Read more
April 17, 2026 The Evidentiary Risks of Natural History Data and How to Approach External Control Comparability Read more
April 16, 2026 Where Master Protocols Are Most Vulnerable Under the Plausible Mechanism Framework Read more
April 15, 2026 How Regulators Assess Substantial Evidence When Trial Populations Are Too Small for Traditional Designs Read more
April 14, 2026 How FDA's Plausible Mechanism Framework Changes the Path to Approval for Individualized Therapies Read more
March 10, 2026 Four strategies for executing complex, international phase 3 breast cancer trials Read more
March 4, 2026 Parexel Execs On Trials In War Zones, Biotech 'Green Shoots', China Action and DCT Rework Read more
March 2, 2026 Scientifically rigorous and resolutely empathetic: how pharmacovigilance programmes can elevate the patient voice Read more
February 27, 2026 Equitable Care, Accelerated Timelines: Expanding Global Access to Rare Disease Research Read more
February 26, 2026 Finding Hope for FRRS1L Selects Parexel for Regulatory and Investigational New Drug (IND) Support with US Food and Drug Administration (FDA) Read more
February 3, 2026 Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions Read more
February 2, 2026 Industry calls Union Budget 2026 a defining moment for India's biopharma future Read more
January 21, 2026 India at a jumping-off point in terms of commitment to global clinical studies Read more
